Safety and tolerance of GnRH agonists in gynecology;Sicherheit und vertraglichkeit von GnRH-agonisten in der gynakologie

Zentralblatt fur Gynakologie

Volumn 121, Issue 7, 1999, Pages 344-348

  Bühler, Klaus ^a  

^a GMP Leidenberger Weise Buhler P   (Germany)

Author keywords

Add back treatment; Assisted reproducive medicine; Coagulation; GnRH agonist; GnRH analogue; Osteoporosis; Safety aspects

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE;

ARTICLE; BLOOD CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INJECTION; INTRANASAL DRUG ADMINISTRATION; LIVER METABOLISM; TERATOGENICITY; UTERUS BLOOD FLOW;

EID: 0344931904     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adamson GD, Heinrichs WL, Henzl MR, Yuzpe AA, Bergquist C, Jacobson JJ, Eriksson S, Kwei L, Gilbert SM: Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel). Am J Obstet Gynecol, 177 (1997) 1413-1418
2. Amstrong SM: Melatonin as a chronbiotic for circadian insomnias: animal models and clinical observations. Hanseatic Endocrine Conference: Melatonin after four decades: An Assessment of its Potential, Hamburg, 1998
3. Bouchard P: GnRH und seine Analoga. Aachen: Unas 1991
4. Broekmans FJ, Hompes PGA, Heitbrink MA, Netelenbos CC, Roos JC, Falke TM, Schoemaker J: Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: Standard-dose therapy followed by reduced-dose therapy. Am J Obstet Gynecol 175 (1996) 1208-1216
5. Bühler K, Winkler U, Scheit S, Rempel E, Schindler AE: Different formulation of GnRH agonists in the treatment of endometriosis. In: GnRH analogues in obstetrics and gynecology. Ed.: Lunenfeld B. Casterton Hall, Carnforth: Parthenon 1992
6. Bühler K, Winkler U, Schindler AE: Influence on Hormone Levels, Lipid Metabolism and Reversibility of Endocrinological Changes after Leuprorelin Acetate Depot Therapy. Clin Therapeutics 14 (1992) Suppl. A, 104-113
7. Bühler K: GnRH agonists and safety. In: GnRH analogues - The state of the art 1993. Eds.: Lunenfeld B, V Insler. Casterton Hall, Carnforth: Parthenon 1993
8. Bühler K: GnRH analogues: safety aspects. In: GnRH analogues - The state of the art 1996. Eds.: Lunenfeld B, V Insler. Casterton Hall, Carnforth: Parthenon 1996
9. Bush TL, Fried LP, Barrett-Connor E: Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 34 (1988) 60-70
10. Caird LE, West CP, Lumsden MA, Hannan WJ, Gow SM: Medroxyprogesterone acetate with ZoladexR for long-term treatment of fibroids: Effects on bone density and patient acceptability. Hum Reprod 12 (1997) 436-440
11. Cedars MI, Lu JKH, Meldrum DR, Judd HL: Treatment of endometriosis with a long-acting gonaclotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 75 (1990) 641-645
12. Candiani GB, Vercellini P, Fedele L, Arcaini L, Bianchi S, Candiani M: Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand 69 (1990) 413-415
13. Cann CE: Bone densitometry as an adjunct to GnRH agonist therapy. J Reprod Med Mar 43 (1998) Suppl., 321-330
14. Christiansen C, Christensen MS, Rodbro P, Hagen C, Transbol I: Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 11 (1981) 305-309
15. Cohen J, de Mouzon J, Lancaster P: World Collaborative Report 1991. Intl. Working Group for Registers on Assisted Reproduction, AIHW National Perinatal Statistics Unit, University of Sydney 1993
16. De Mouzon J, Lancaster P: World Collaborative Report 1993. Intl. Working Group for Registers on Assisted Reproduction, AIHW National Perinatal Statistics Unit, University of Sydney 1995
17. DIR - Deutsches IVF Register, Jahrbuch 1995; DIR Bundesgeschäftsstelle
18. Dossier FIVNAT 93. Association FIVNAT; Thépot F; CHI Jean-Rostand, Sèvres 1994
19. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. New Engl J Med 331 (1994) 1618-1623
20. Friedman AJ, Barbieri RL: Leuprolide acetate: applications in gynecology. Curr Probl Obstet Gynecol Fertil 11 (1988) 205-236
21. Hornstein MD, Surrey ES, Weisberg GW, Casino LA: Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study. Obstet Gynecol 91 (1998) 16-24
22. Newhall-Perry K, Holloway L, Osburn L, Monroe SE, Heinrichs L, Henzl M, Marcus R: Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis. Am J Obstet Gynecol 173 (1995) 824-829
23. Rico H, Arnanz F, Revilla M, Perera S, Iritia M, Villa LF, Arribas I: Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 52 (1993) 354-357
24. Scialli AR, Jestila KJ, Simon JA: Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fertil Steril 59 (1993) 674-676
25. Surrey ES, Judd HL: Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting-gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. J Clin Endocrinol Metab 75 (1992) 558-563
26. Taga M, Minaguchi H: Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75 (1996) 162-165
27. Winkler U, Bühler K, Koslowski S, Oberhoff C, Schindler AE: Plasmatic Haemostasis in Gonadotrophin-Releasing Hormone Analogue Therapy: Effects of Leuprorelin Acetate Depot on Coagulatory and Fibrinolytic Activities. Clin Therapeutics 14 (1992) Suppl. A, 114-120
28. Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S: Intermittent etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. Osteoporosis Int 7 (1997) 133-137